SCHEMBL25433103

SCHEMBL25433103

C[C@@H]1c2cc(Br)nn2CCN1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.41
RIPK1 Q13546 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26645168 1.00 GRM5 (0.41) GRM5RIPK1KDM4EMEN1ALDH1A1
SCHEMBL26026951 0.82 GRM5 (0.36) GRM5KDM4EMEN1ALDH1A1MAPT
SCHEMBL25430590 0.78 GRM5 (0.39) GRM5
SCHEMBL25434081 0.78 GRM5 (0.39) GRM5
SCHEMBL25431709 0.78 GRM5 (0.39) GRM5
SCHEMBL25431327 0.76 CPS1 (0.30)
SCHEMBL26645195 0.76
SCHEMBL25431542 0.76 CPS1 (0.30)
SCHEMBL25429422 0.76
SCHEMBL26645678 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519265-A1 IRREVERSIBLE MUTEGFR INHIBITORS Bayer Aktiengesellschaft (DE) 2025-03-12 EP disclosed
WO-2023213882-A1 IRREVERSIBLE MUTEGFR INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-11-09 WO disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed